

Technical Information

Columbia C.N.A. Agar Base

Product Code: DM 1560A

Application: - Columbia Broth Base is used as a general-purpose medium and also for the cultivation of fastidious organisms.

Composition**

Ingredients	Gms / Litre
Biopeptone	20.000
Tryptic digest of beef heart	3.000
Corn starch	1.000
Sodium chloride	5.000
Colistin sulphate	0.010
Nalidixic acid	0.015
Agar	15.000
Final pH (at 25°C)	7.3±0.2

**Formula adjusted, standardized to suit performance parameters

Principle & Interpretation

Columbia Agar Base is a nutritionally rich formula containing 5% defibrinated blood, which provides more nutrients and capability of displaying haemolytic reactions. Ellner et al formulated the medium ⁽¹⁾ and found that the combination of peptones used gave more rapid and abundant growth of Streptococci, Staphylococci, *Neisseria* and *Haemophilus* with better-defined haemolytic reactions. Columbia C.N.A. Agar Base is prepared with the same formula as Columbia Agar Base with the addition of 10 mg/litre of colistin and 15 mg/ litre of nalidixic acid to inhibit the growth of gram-negative bacteria and to support the growth of Staphylococci, haemolytic Streptococci and Enterococci when supplemented with 5% blood.

Biopeptone and tryptic digest of beef heart supports luxuriant growth of microorganisms and visualization of good haemolytic reactions. Sheep blood allows detection of haemolytic reactions and supplies X-factor necessary for the growth of many bacterial species. Horse blood supplies both X-factor and V-factor, therefore is mostly preferred in most laboratories. Yeast extract and cornstarch serve as energy source and neutralizer respectively.

It should be noted that this medium has relatively high carbohydrate content and, therefore, beta-hemolytic streptococci may produce a greenish hemolytic reaction that may be mistaken for alpha haemolysis. The addition of the antimicrobial agents, colistin (or polymyxin B) and nalidixic acid, renders the medium selective for gram-positive microorganisms ⁽²⁾. Colistin and nalidixic acid disrupt the cell membrane of gram-negative organisms, whereas nalidixic acid blocks DNA replication in susceptible gram-negative bacteria ⁽³⁾.

Columbia C.N.A. Agar Base with addition of blood Also used for selective isolation of *Gardnerella vaginalis*. This medium supports growth of *Brucella abortus*, *Yersinia pestis*, *Clostridium perfringens* and all commonly occurring *Enterobacteriaceae* without addition of blood.

Methodology

Suspend 44.02 grams of powder media in 1000 ml distilled water. Shake well and heat to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Cool to 50°C and aseptically add 5% v/v sterile, defibrinated blood. Mix well and pour into sterile Petri plates.

Quality Control

Physical Appearance

Cream to yellow homogeneous free flowing powder

Gelling

Firm, comparable with 1.5% Agar gel

Colour and Clarity of prepared medium

Basal medium: Yellow coloured clear to slightly opalescent gel. After addition of 5% v/v sterile defibrinated blood: Cherry red coloured opaque gel forms in Petri plates

Reaction

Reaction of 4.4% w/v aqueous solution at 25°C. pH : 7.3±0.2

pH range 7.10-7.50

Cultural Response

DM 1560A: Cultural characteristics observed with added 5% v/v sterile, defibrinated blood after an incubation at 35-37°C for 40-48 hours.

Organism	Inoculum (CFU)	Growth	Recovery	Haemolysis
<i>Escherichia coli</i> ATCC 25922	$\geq 10^3$	inhibited	0%	
<i>Neisseria meningitidis</i> ATCC 13090	$\geq 10^3$	inhibited	0%	
<i>Staphylococcus aureus</i> ATCC 25923	50-100	luxuriant	$\geq 50\%$	beta/gamma
<i>Staphylococcus epidermidis</i> ATCC 12228	50-100	luxuriant	$\geq 50\%$	gamma
<i>Streptococcus pneumoniae</i> ATCC 6303	50-100	luxuriant	$\geq 50\%$	alpha
<i>Streptococcus pyogenes</i> ATCC 19615	50-100	luxuriant	$\geq 50\%$	beta

Storage and Shelf Life

Dried Media: Store below 30°C in tightly closed container and use before expiry date as mentioned on the label.

Prepared Media: 2-8° in sealable plastic bags for 2-5 days.

Further Reading

1. Ellner et al, 1966, Am. J. Clin. Path., 45:502.
2. Murray P. R., Baron J. H., Tenover F. C., Tenover J. C., (Ed.), 2003, Manual of Clinical Microbiology, 8th Ed., American Society for Microbiology, Washington, D.C.
3. Estevez, 1984, Lab. Med., 15:258

Disclaimer :

- User must ensure suitability of the product(s) in their application prior to use.
- The product conform solely to the technical information provided in this booklet and to the best of knowledge research and development work carried at **CDH** is true and accurate
- **Central Drug House Pvt. Ltd.** reserves the right to make changes to specifications and information related to the products at any time.
- Products are not intended for human or animal diagnostic or therapeutic use but for laboratory, research or further manufacturing of diagnostic reagents extra.
- Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.
- Do not use the products if it fails to meet specifications for identity and performance parameters.